{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:48:20Z","timestamp":1791413300380,"version":"4.3.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,23]],"date-time":"2015-04-23T00:00:00Z","timestamp":1429747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s11926-015-0512-5","type":"journal-article","created":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T02:06:19Z","timestamp":1429668379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Tumor-Induced Osteomalacia: an Up-to-Date Review"],"prefix":"10.1007","volume":"17","author":[{"given":"Anke H.","family":"Hautmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias G.","family":"Hautmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"K\u00f6lbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,23]]},"reference":[{"issue":"2","key":"512_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010006811394","volume":"2","author":"MK Drezner","year":"2001","unstructured":"Drezner MK. Tumor-induced osteomalacia. Rev Endocr Metab Disord. 2001;2(2):175\u201386.","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"512_CR2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan Beur de","year":"2005","unstructured":"de Jan Beur SM. Tumor-induced osteomalacia. JAMA: J Am Med Assoc. 2005;294(10):1260\u20137.","journal-title":"JAMA: J Am Med Assoc"},{"issue":"3","key":"512_CR3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1210\/er.2005-0019","volume":"27","author":"KE White","year":"2006","unstructured":"White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr Rev. 2006;27(3):221\u201341.","journal-title":"Endocr Rev"},{"issue":"9","key":"512_CR4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s10067-006-0468-y","volume":"26","author":"M Kaul","year":"2007","unstructured":"Kaul M, Silverberg M, DiCarlo E, et al. Tumor-induced osteomalacia. Clin Rheumatol. 2007;26(9):1575\u20139.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"512_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00223-009-9275-1","volume":"85","author":"D Rendina","year":"2009","unstructured":"Rendina D, de Filippo G, Tauchmanov\u00e0 L, et al. Bone turnover and the osteoprotegerin\u2013RANKL pathway in tumor-induced osteomalacia: a longitudinal study of five cases. Calcif Tissue Int. 2009;85(4):293\u2013300.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"512_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-011-0340-2","volume":"30","author":"T Carpenter","year":"2012","unstructured":"Carpenter T. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab. 2012;30(1):1\u20139.","journal-title":"J Bone Miner Metab"},{"key":"512_CR7","doi-asserted-by":"crossref","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28 (1).","DOI":"10.1097\/00000478-200401000-00001"},{"issue":"6","key":"512_CR8","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.tripleo.2009.07.005","volume":"108","author":"VL Woo","year":"2009","unstructured":"Woo VL, Landesberg R, Imel EA, et al. Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108(6):925\u201332.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"512_CR9","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/j.tripleo.2009.10.052","volume":"109","author":"Y Mori","year":"2010","unstructured":"Mori Y, Ogasawara T, Motoi T, et al. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e57\u201363.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"512_CR10","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH, Molinolo AA, Chen CC, et al. Tumor-induced osteomalacia. Endocr-Relat Cancer. 2011;18(3):R53\u201377. Worth reading overview about the literature and the differential diagnosis of TIO.","journal-title":"Endocr-Relat Cancer"},{"issue":"12","key":"512_CR11","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1210\/jc.2011-1757","volume":"96","author":"WH Chong","year":"2011","unstructured":"Chong WH, Yavuz S, Patel SM, et al. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2011;96(12):3599\u2013600.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"512_CR12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nrrheum.2014.138","volume":"10","author":"B Manger","year":"2014","unstructured":"Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10(11):662\u201370.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"512_CR13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/154411130401500503","volume":"15","author":"PSN Rowe","year":"2004","unstructured":"Rowe PSN. The wrickkened pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med. 2004;15(5):264\u201381.","journal-title":"Crit Rev Oral Biol Med"},{"issue":"1","key":"512_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00774-011-0290-8","volume":"30","author":"Y Imanishi","year":"2012","unstructured":"Imanishi Y, Hashimoto J, Ando W, et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J Bone Miner Metab. 2012;30(1):93\u20139.","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"512_CR15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1210\/jc.2012-3473","volume":"98","author":"DE Leaf","year":"2013","unstructured":"Leaf DE, Pereira RC, Bazari H, et al. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab. 2013;98(3):887\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"512_CR16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/1346-8138.12602","volume":"41","author":"R Honda","year":"2014","unstructured":"Honda R, Kawabata Y, Ito S, et al. Phosphaturic mesenchymal tumor, mixed connective tissue type, non-phosphaturic variant: report of a case and review of 32 cases from the Japanese published work. J Dermatol. 2014;41(9):845\u20139. Excellent overview about the recently published literature.","journal-title":"J Dermatol"},{"issue":"11","key":"512_CR17","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1007\/s11999-013-3178-1","volume":"471","author":"CK Ledford","year":"2013","unstructured":"Ledford CK, Zelenski NA, Cardona DM, et al. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop Relat Res. 2013;471(11):3618\u201325.","journal-title":"Clin Orthop Relat Res"},{"key":"512_CR18","doi-asserted-by":"crossref","unstructured":"Duet M, Kerkeni S, Sfar R, et al. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med. 2008;33 (11).","DOI":"10.1097\/RLU.0b013e31818866bf"},{"issue":"10","key":"512_CR19","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1210\/jc.2010-0543","volume":"95","author":"G Haeusler","year":"2010","unstructured":"Haeusler G, Freilinger M, Dominkus M, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy\u2014clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95(10):4511\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"512_CR20","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","volume":"44","author":"M Houang","year":"2013","unstructured":"Houang M, Clarkson A, Sioson L, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711\u20138.","journal-title":"Hum Pathol"},{"key":"512_CR21","first-page":"729387","volume":"2014","author":"AH Hautmann","year":"2014","unstructured":"Hautmann AH, Schroeder J, Wild P, et al. Tumor-induced osteomalacia: increased level of FGF-23 in a patient with a phosphaturic mesenchymal tumor at the tibia expressing periostin. Case Rep Endocrinol. 2014;2014:729387. Interesting case report with new findings in immunohistochemical stainings and review of the recently published literature.","journal-title":"Case Rep Endocrinol"},{"issue":"5","key":"512_CR22","first-page":"1628","volume":"80","author":"GE Wilkins","year":"1995","unstructured":"Wilkins GE, Granleese S, Hegele RG, et al. Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab. 1995;80(5):1628\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"512_CR23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00428-005-0149-2","volume":"448","author":"K Shelekhova","year":"2006","unstructured":"Shelekhova K, Kazakov D, Hes O, et al. Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis. Virchows Arch. 2006;448(2):232\u20135.","journal-title":"Virchows Arch"},{"issue":"2","key":"512_CR24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/path.1711670204","volume":"167","author":"MD Stone","year":"1992","unstructured":"Stone MD, Quincey C, Hosking DJ. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 1992;167(2):181\u20135.","journal-title":"J Pathol"},{"key":"512_CR25","doi-asserted-by":"crossref","unstructured":"Malhotra G, Agrawal A, Jambhekar NA, et al. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med. 2010;35 (11).","DOI":"10.1097\/RLU.0b013e3181f49e69"},{"issue":"1","key":"512_CR26","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","volume":"40","author":"K Agrawal","year":"2015","unstructured":"Agrawal K, Bhadada S, Mittal BR, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40(1):e6\u2013e10.","journal-title":"Clin Nucl Med"},{"key":"512_CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2014.04.016","volume":"64","author":"S Breer","year":"2014","unstructured":"Breer S, Brunkhorst T, Beil FT, et al. 68Ga DOTA-TATE PET\/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT\/CT. Bone. 2014;64:222\u20137.","journal-title":"Bone"},{"issue":"2","key":"512_CR28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3803\/EnM.2014.29.2.136","volume":"29","author":"S Fukumoto","year":"2014","unstructured":"Fukumoto S. Diagnostic modalities for FGF23-producing tumors in patients with tumor-induced osteomalacia. Endocrinol Metab. 2014;29(2):136\u201343.","journal-title":"Endocrinol Metab"},{"issue":"1","key":"512_CR29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0360-3016(03)00416-4","volume":"57","author":"JJ Caudell","year":"2003","unstructured":"Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 2003;57(1):158\u201365.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"512_CR30","first-page":"1217","volume":"24","author":"Y Kinoshita","year":"2014","unstructured":"Kinoshita Y, Fukumoto S. [Anti-FGF23 antibody therapy for patients with tumor-induced osteomalacia]. Clin Calcium. 2014;24(8):1217\u201322.","journal-title":"Clin Calcium"},{"issue":"26","key":"512_CR31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","volume":"345","author":"J Seufert","year":"2001","unstructured":"Seufert J, Ebert K, M\u00fcller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med. 2001;345(26):1883\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"512_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002560000306","volume":"30","author":"A Ogose","year":"2001","unstructured":"Ogose A, Hotta T, Emura I, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001;30(2):99\u2013103.","journal-title":"Skeletal Radiol"},{"issue":"1","key":"512_CR33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3892\/ol.2014.2081","volume":"8","author":"T MORIMOTO","year":"2014","unstructured":"MORIMOTO T, TAKENAKA S, HASHIMOTO N, et al. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol Lett. 2014;8(1):67\u201371.","journal-title":"Oncol Lett"},{"key":"512_CR34","doi-asserted-by":"crossref","unstructured":"Mendenhall WM, Zlotecki RA, Scarborough MT, et al. Giant cell tumor of bone. Am J Clin Oncol. 2006;29 (1).","DOI":"10.1097\/01.coc.0000195089.11620.b7"},{"key":"512_CR35","doi-asserted-by":"crossref","unstructured":"Tarasova VD, Trepp-Carrasco AG, Thompson R, et al. Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clinical Endocrinol Metab. 2013.","DOI":"10.1210\/jc.2013-2528"},{"key":"512_CR36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/01.blo.0000069890.31220.b4","volume":"411","author":"SJ Feigenberg","year":"2003","unstructured":"Feigenberg SJ, Marcus Jr RB, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res. 2003;411:207\u201316.","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"512_CR37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0360-3016(00)01520-0","volume":"49","author":"L Miszczyk","year":"2001","unstructured":"Miszczyk L, Wydma\u0144ski J, Spindel J. Efficacy of radiotherapy for giant cell tumor of bone: given either postoperatively or as sole treatment. Int J Radiat Oncol Biol Phys. 2001;49(5):1239\u201342.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"512_CR38","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0360-3016(95)00159-V","volume":"33","author":"S Malone","year":"1995","unstructured":"Malone S, O\u2019Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 1995;33(3):689\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"512_CR39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ijrobp.2009.07.1704","volume":"78","author":"W Ruka","year":"2010","unstructured":"Ruka W, Rutkowski P, Morysi\u0144ski T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys. 2010;78(2):494\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"512_CR40","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0360-3016(98)00526-4","volume":"43","author":"MK Nair","year":"1999","unstructured":"Nair MK, Jyothirmayi R. Radiation therapy in the treatment of giant cell tumor of bone. Int J Radiat Oncol Biol Phys. 1999;43(5):1065\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"512_CR41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1227\/NEU.0b013e31827b9e68","volume":"72","author":"AJ Ghia","year":"2013","unstructured":"Ghia AJ, Allen PK, Mahajan A, et al. Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery. 2013;72(2):203\u20139.","journal-title":"Neurosurgery"},{"issue":"2","key":"512_CR42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3171\/2013.10.JNS13113","volume":"120","author":"AM Sonabend","year":"2014","unstructured":"Sonabend AM, Zacharia BE, Goldstein H, et al. The role for adjuvant radiotherapy in the treatment of hemangiopericytoma: a Surveillance, Epidemiology, and End Results analysis. J Neurosurg. 2014;120(2):300\u20138.","journal-title":"J Neurosurg"},{"issue":"1","key":"512_CR43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00701-007-1474-9","volume":"150","author":"R Jalali","year":"2008","unstructured":"Jalali R, Srinivas C, Nadkarni TD, et al. Suprasellar haemangiopericytoma\u2014challenges in diagnosis and treatment. Acta Neurochir (Wien). 2008;150(1):67\u201371.","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"512_CR44","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1227\/00006123-198910000-00003","volume":"25","author":"BL Guthrie","year":"1989","unstructured":"Guthrie BL, Ebersold MJ, Scheithauer BW, et al. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989;25(4):514\u201322.","journal-title":"Neurosurgery"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0512-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-015-0512-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-015-0512-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T22:31:14Z","timestamp":1566599474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-015-0512-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,23]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1007\/s11926-015-0512-5","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,23]]},"article-number":"37"}}